Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Isomorphic Labs›
Analysis
AddedMay 14, 2026
UpdatedJul 15, 2026
Isomorphic Labs

Isomorphic Labs

Series B

Isomorphic Labs is an Alphabet-backed biotechnology company pioneering AI-driven drug discovery with a unified drug design engine.

HQ
London, GB
Founded
2021
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Website

Contents

  1. 01Products & Services
  2. 02Market Outlook
  3. 03Competitive Strengths
  1. 01Products & Services
  2. 02Market Outlook
  3. 03Competitive Strengths

Product Overview

Isomorphic Labs' Drug Design Engine is an AI-first platform that builds on the Nobel-winning AlphaFold system to predict biomolecular structures and interactions with high accuracy. It integrates structural biology, chemistry, and machine learning to generate and optimize drug candidates across modalities such as small molecules, antibodies, peptides, and molecular glues.

The engine is designed to accelerate the discovery of novel therapeutics by modeling complex biological phenomena digitally, enabling researchers to anticipate how drug candidates will perform before entering the laboratory.

Market Outlook

Isomorphic Labs operates at the intersection of artificial intelligence and pharmaceutical research, a sector poised to transform how medicines are discovered and developed. Its platform addresses the longstanding challenge of predicting biomolecular behavior, potentially compressing discovery timelines and improving success rates.

The company is advancing programs across multiple therapeutic areas and modalities, positioning it to partner broadly with the biopharmaceutical industry while pursuing its long-term mission to one day solve all disease with the help of AI.

Competitive Advantages

Isomorphic Labs combines Nobel-winning AlphaFold technology with a purpose-built AI drug design engine, giving it deep expertise in both structural biology and large-scale machine learning. Its close relationship with Alphabet and Google DeepMind provides access to world-class compute infrastructure and frontier research.

The company has secured high-value partnerships with Novartis, Johnson & Johnson, and Eli Lilly, validating its platform across multiple therapeutic areas and drug modalities including small molecules, antibodies, peptides, and molecular glues.